

Douglas Sato

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6078307/publications.pdf>

Version: 2024-02-01

91
papers

5,654
citations

109321

35
h-index

79698

73
g-index

93
all docs

93
docs citations

93
times ranked

4040
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. <i>Neurology</i> , 2014, 82, 474-481. | 1.1 | 743 |
| 2 | MRI characteristics of neuromyelitis optica spectrum disorder. <i>Neurology</i> , 2015, 84, 1165-1173. | 1.1 | 523 |
| 3 | MOG antibody-positive, benign, unilateral, cerebral cortical encephalitis with epilepsy. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017, 4, e322. | 6.0 | 334 |
| 4 | MOG cell-based assay detects non-MS patients with inflammatory neurologic disease. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e89. | 6.0 | 322 |
| 5 | Demographic and clinical features of neuromyelitis optica: A review. <i>Multiple Sclerosis Journal</i> , 2015, 21, 845-853. | 3.0 | 278 |
| 6 | Myelin-oligodendrocyte glycoprotein antibody-associated disease. <i>Lancet Neurology</i> , The, 2021, 20, 762-772. | 10.2 | 261 |
| 7 | Neuromyelitis optica and multiple sclerosis: Seeing differences through optical coherence tomography. <i>Multiple Sclerosis Journal</i> , 2015, 21, 678-688. | 3.0 | 209 |
| 8 | Myasthenia gravis and neuromyelitis optica spectrum disorder. <i>Neurology</i> , 2012, 78, 1601-1607. | 1.1 | 177 |
| 9 | MOG-IgG-Associated Optic Neuritis, Encephalitis, and Myelitis: Lessons Learned From Neuromyelitis Optica Spectrum Disorder. <i>Frontiers in Neurology</i> , 2018, 9, 217. | 2.4 | 156 |
| 10 | Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 922-930. | 1.9 | 149 |
| 11 | MRI and retinal abnormalities in isolated optic neuritis with myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies: a comparative study: Table A1. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 446-448. | 1.9 | 134 |
| 12 | CSF cytokine profile in MOG-IgG+ neurological disease is similar to AQP4-IgG+ NMOSD but distinct from MS: a cross-sectional study and potential therapeutic implications. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 927-936. | 1.9 | 116 |
| 13 | Bilateral frontal cortex encephalitis and paraparesis in a patient with anti-MOG antibodies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 534-536. | 1.9 | 113 |
| 14 | Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 44, 102251. | 2.0 | 110 |
| 15 | Update on biomarkers in neuromyelitis optica. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e134. | 6.0 | 104 |
| 16 | Aquaporin-4 antibody-positive cases beyond current diagnostic criteria for NMO spectrum disorders. <i>Neurology</i> , 2013, 80, 2210-2216. | 1.1 | 98 |
| 17 | Th17 Cells Pathways in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders: Pathophysiological and Therapeutic Implications. <i>Mediators of Inflammation</i> , 2016, 2016, 1-11. | 3.0 | 92 |
| 18 | Myelin injury without astrocytopathy in neuroinflammatory disorders with MOG antibodies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1257-1259. | 1.9 | 89 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Lesion length of optic neuritis impacts visual prognosis in neuromyelitis optica. <i>Journal of Neuroimmunology</i> , 2016, 293, 28-33. | 2.3 | 81 |
| 20 | Neuromyelitis optica should be classified as an astrocytopathic disease rather than a demyelinating disease. <i>Clinical and Experimental Neuroimmunology</i> , 2012, 3, 58-73. | 1.0 | 79 |
| 21 | Fulminant demyelinating encephalomyelitis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e175. | 6.0 | 75 |
| 22 | Treatment of MOG antibody associated disorders: results of an international survey. <i>Journal of Neurology</i> , 2020, 267, 3565-3577. | 3.6 | 64 |
| 23 | Severe demyelination but no astrocytopathy in clinically definite neuromyelitis optica with anti-myelin-oligodendrocyte glycoprotein antibody. <i>Multiple Sclerosis Journal</i> , 2015, 21, 656-659. | 3.0 | 63 |
| 24 | Different etiologies and prognoses of optic neuritis in demyelinating diseases. <i>Journal of Neuroimmunology</i> , 2016, 299, 152-157. | 2.3 | 63 |
| 25 | Use of Advanced Magnetic Resonance Imaging Techniques in Neuromyelitis Optica Spectrum Disorder. <i>JAMA Neurology</i> , 2015, 72, 815. | 9.0 | 59 |
| 26 | Highly encephalitogenic aquaporin 4-specific T cells and NMO-IgG jointly orchestrate lesion location and tissue damage in the CNS. <i>Acta Neuropathologica</i> , 2015, 130, 783-798. | 7.7 | 55 |
| 27 | Severely exacerbated neuromyelitis optica rat model with extensive astrocytopathy by high affinity anti-aquaporin-4 monoclonal antibody. <i>Acta Neuropathologica Communications</i> , 2015, 3, 82. | 5.2 | 54 |
| 28 | Neuromyelitis Optica Spectrum Disorders. <i>Neuroimaging Clinics of North America</i> , 2017, 27, 251-265. | 1.0 | 53 |
| 29 | Changes in Th17 and regulatory T cells after fingolimod initiation to treat multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2014, 268, 95-98. | 2.3 | 50 |
| 30 | Cerebrospinal fluid aquaporin-4 antibody levels in neuromyelitis optica attacks. <i>Annals of Neurology</i> , 2014, 76, 305-309. | 5.3 | 49 |
| 31 | Persistent MOG-IgG positivity is a predictor of recurrence in MOG-IgG-associated optic neuritis, encephalitis and myelitis. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1907-1914. | 3.0 | 45 |
| 32 | Viral encephalitis: a practical review on diagnostic approach and treatment. <i>Jornal De Pediatria</i> , 2020, 96, 12-19. | 2.0 | 44 |
| 33 | Treatment of neuromyelitis optica: an evidence based review. <i>Arquivos De Neuro-Psiquiatria</i> , 2012, 70, 59-66. | 0.8 | 43 |
| 34 | Latin American consensus recommendations for management and treatment of neuromyelitis optica spectrum disorders in clinical practice. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 45, 102428. | 2.0 | 42 |
| 35 | Influenza-associated MOG antibody-positive longitudinally extensive transverse myelitis: a case report. <i>BMC Neurology</i> , 2014, 14, 224. | 1.8 | 40 |
| 36 | Treatment and outcome of aquaporin-4 antibody-positive NMOSD. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, . | 6.0 | 37 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Clinical Spectrum and Treatment of Neuromyelitis Optica Spectrum Disorders: Evolution and Current Status. <i>Brain Pathology</i> , 2013, 23, 647-660. | 4.1 | 36 |
| 38 | Clinical spectrum of inflammatory central nervous system demyelinating disorders associated with antibodies against myelin oligodendrocyte glycoprotein. <i>Neurochemistry International</i> , 2019, 130, 104319. | 3.8 | 35 |
| 39 | The clinical spectrum associated with myelin oligodendrocyte glycoprotein antibodies (anti-MOG-Ab) in Thai patients. <i>Multiple Sclerosis Journal</i> , 2016, 22, 964-968. | 3.0 | 31 |
| 40 | Clinical features and long-term outcome of a group of Japanese children with inflammatory central nervous system disorders and seropositivity to myelin-oligodendrocyte glycoprotein antibodies. <i>Brain and Development</i> , 2015, 37, 849-852. | 1.1 | 30 |
| 41 | Atypical presentations of neuromyelitis optica. <i>Arquivos De Neuro-Psiquiatria</i> , 2011, 69, 824-828. | 0.8 | 29 |
| 42 | Seronegative Neuromyelitis Optica Spectrum - The challenges on disease definition and pathogenesis. <i>Arquivos De Neuro-Psiquiatria</i> , 2014, 72, 445-450. | 0.8 | 25 |
| 43 | Idiopathic aquaporin-4 antibody negative longitudinally extensive transverse myelitis. <i>Multiple Sclerosis Journal</i> , 2015, 21, 710-717. | 3.0 | 25 |
| 44 | Serological markers associated with neuromyelitis optica spectrum disorders in South India. <i>Annals of Indian Academy of Neurology</i> , 2016, 19, 505. | 0.5 | 24 |
| 45 | Brazilian Consensus for the Treatment of Multiple Sclerosis: Brazilian Academy of Neurology and Brazilian Committee on Treatment and Research in Multiple Sclerosis. <i>Arquivos De Neuro-Psiquiatria</i> , 2018, 76, 539-554. | 0.8 | 22 |
| 46 | Correlation between the corpus callosum index and brain atrophy, lesion load, and cognitive dysfunction in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 20, 154-158. | 2.0 | 20 |
| 47 | Post-vaccination MDEM associated with MOG antibody in a subclinical Chlamydia infected boy. <i>Brain and Development</i> , 2016, 38, 690-693. | 1.1 | 19 |
| 48 | Role of Glutamatergic Excitotoxicity in Neuromyelitis Optica Spectrum Disorders. <i>Frontiers in Cellular Neuroscience</i> , 2019, 13, 142. | 3.7 | 19 |
| 49 | Anti- α -methyl-D-aspartate receptor encephalitis with multiphasic demyelination. <i>Annals of Neurology</i> , 2014, 76, 462-464. | 5.3 | 18 |
| 50 | MOG-antibody-associated disease is different from MS and NMOSD and should be considered as a distinct disease entity – Yes. <i>Multiple Sclerosis Journal</i> , 2020, 26, 272-274. | 3.0 | 18 |
| 51 | Status of the neuromyelitis optica spectrum disorder in Latin America. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 53, 103083. | 2.0 | 18 |
| 52 | Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. <i>Neurology</i> , 2014, 83, 1122-1123. | 1.1 | 17 |
| 53 | CSF levels of glutamine synthetase and GFAP to explore astrocytic damage in seronegative NMOSD. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 605-611. | 1.9 | 17 |
| 54 | Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. <i>Neurology</i> , 2014, 83, 475-476. | 1.1 | 16 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Characterization of pain syndromes in patients with neuromyelitis optica. <i>European Journal of Pain</i> , 2020, 24, 1548-1568. | 2.8 | 16 |
| 56 | Relapsing optic neuritis and isolated transverse myelitis are the predominant clinical phenotypes for patients with antibodies to myelin oligodendrocyte glycoprotein in India. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2016, 2, 205521731667563. | 1.0 | 15 |
| 57 | Neutralizing Antibodies Are Associated with a Reduction of Interferon- β Efficacy during the Treatment of Japanese Multiple Sclerosis Patients. <i>Tohoku Journal of Experimental Medicine</i> , 2012, 228, 85-92. | 1.2 | 14 |
| 58 | Detection of MOG-IgG by cell-based assay: moving from discovery to clinical practice. <i>Neurological Sciences</i> , 2021, 42, 73-80. | 1.9 | 14 |
| 59 | Myelin oligodendrocyte glycoprotein immunoglobulin G-associated disease: An overview. <i>Clinical and Experimental Neuroimmunology</i> , 2018, 9, 48-55. | 1.0 | 13 |
| 60 | AQP4 antibody serostatus. <i>Neurology</i> , 2013, 81, 1186-1188. | 1.1 | 12 |
| 61 | Anti-MOG (Myelin Oligodendrocyte Glycoprotein)-Positive Severe Optic Neuritis with Optic Disc Ischaemia and Macular Star. <i>Neuro-Ophthalmology</i> , 2015, 39, 285-288. | 1.0 | 12 |
| 62 | Experimental Models of Neuroimmunological Disorders: A Review. <i>Frontiers in Neurology</i> , 2020, 11, 389. | 2.4 | 11 |
| 63 | Aquaporin-4 antibody-positive myelitis initially biopsied for suspected spinal cord tumors: Diagnostic considerations. <i>Multiple Sclerosis Journal</i> , 2014, 20, 621-626. | 3.0 | 10 |
| 64 | Unraveling B lymphocytes in CNS inflammatory diseases. <i>Neurology</i> , 2020, 95, 733-744. | 1.1 | 10 |
| 65 | Treatment of MOG-IgG associated disease in paediatric patients: A systematic review. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 56, 103216. | 2.0 | 10 |
| 66 | Neuromyelitis optica without typical opticospinal phenotype. <i>Multiple Sclerosis Journal</i> , 2010, 16, 1154-1155. | 3.0 | 9 |
| 67 | MOG-IgG serological status matters in paediatric ADEM. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 242-242. | 1.9 | 8 |
| 68 | MOG-IgG associated optic neuritis is not multiple sclerosis. <i>Arquivos De Neuro-Psiquiatria</i> , 2017, 75, 687-691. | 0.8 | 8 |
| 69 | Detection of autoantibodies in central nervous system inflammatory disorders: Clinical application of cell-based assays. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 38, 101858. | 2.0 | 8 |
| 70 | Consensus recommendations for the diagnosis and treatment of primary progressive multiple sclerosis in Latin America. <i>Journal of the Neurological Sciences</i> , 2018, 393, 4-13. | 0.6 | 7 |
| 71 | Viral encephalitis: a practical review on diagnostic approach and treatment. <i>Jornal De Pediatria (Versão Em Português)</i> , 2020, 96, 12-19. | 0.2 | 7 |
| 72 | Safety indicators of a novel multi supplement based on guarana, selenium, and L-carnitine: Evidence from human and red earthworm immune cells. <i>Food and Chemical Toxicology</i> , 2021, 150, 112066. | 3.6 | 6 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Long-term safety of azathioprine for treatment of neuromyelitis optica spectrum disorders. <i>Arquivos De Neuro-Psiquiatria</i> , 2021, 79, 229-232. | 0.8 | 5 |
| 74 | Decreased convulsive threshold and memory loss after anti-NMDAR positive CSF injection in zebrafish. <i>Journal of Neuroimmunology</i> , 2021, 359, 577689. | 2.3 | 5 |
| 75 | Mechanisms of myelin repair, MRI techniques and therapeutic opportunities in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 58, 103407. | 2.0 | 5 |
| 76 | Detection of MOG-IgG in Clinical Samples by Live Cell-Based Assays: Performance of Immunofluorescence Microscopy and Flow Cytometry. <i>Frontiers in Immunology</i> , 2021, 12, 642272. | 4.8 | 4 |
| 77 | Case of autoantibodies against N-methyl-D-aspartate receptor+/antibodies against myelin oligodendrocyte glycoprotein+ multiphasic acute disseminated encephalomyelitis (<scp>ADEM</scp>). <i>Clinical and Experimental Neuroimmunology</i> , 2014, 5, 49-51. | 1.0 | 3 |
| 78 | Reduced quality of life in a pediatric-onset Neuromyelitis optica spectrum disorders cohort. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 56, 103252. | 2.0 | 3 |
| 79 | Time to target brain atrophy and neurodegeneration in multiple sclerosis. <i>Arquivos De Neuro-Psiquiatria</i> , 2016, 74, 181-182. | 0.8 | 2 |
| 80 | Oral fingolimod to treat multiple sclerosis: see your cardiologist first. <i>Arquivos De Neuro-Psiquiatria</i> , 2014, 72, 651-652. | 0.8 | 2 |
| 81 | Aquaporin-4 antibody-positive cases beyond current diagnostic criteria for NMO spectrum disorders. <i>Neurology</i> , 2014, 82, 372-372. | 1.1 | 1 |
| 82 | Leukoencephalopathy resolution after atypical mycobacterial treatment: a case report. <i>BMC Neurology</i> , 2015, 15, 159. | 1.8 | 1 |
| 83 | Healthy aging during the COVID-19 pandemic. <i>PAJAR - Pan-American Journal of Aging Research</i> , 2021, 9, e41087. | 0.1 | 1 |
| 84 | Simultaneous bilateral optic neuritis and longitudinally extensive transverse myelitis following vaccination against COVID-19: A case report. <i>Neuroimmunology Reports</i> , 2021, 1, 100041. | 0.4 | 1 |
| 85 | 2014 Joint Americas Committee for Treatment and Research in Multiple Sclerosis“European Committee for Treatment and Research in Multiple Sclerosis Meeting. <i>Clinical and Experimental Neuroimmunology</i> , 2015, 6, 100-102. | 1.0 | 0 |
| 86 | A Regional Analysis of Relapsing Remitting MS (RRMS) Patients Treated with Natalizumab Suggests a Need to Diagnose and Treat Early in Latin Americans. <i>Value in Health</i> , 2016, 19, A437. | 0.3 | 0 |
| 87 | Autoimmune encephalitis in patients with anti-myelin oligodendrocyte glycoprotein-antibody. <i>Journal of the Neurological Sciences</i> , 2017, 381, 792. | 0.6 | 0 |
| 88 | Discrimination of spinal cord sarcoidosis from neuromyelitis optica spectrum disorder or spondylotic myelopathy. <i>Journal of the Neurological Sciences</i> , 2017, 381, 449-450. | 0.6 | 0 |
| 89 | Sometimes less is more in multiple sclerosis drug switching. <i>Arquivos De Neuro-Psiquiatria</i> , 2016, 74, 605-606. | 0.8 | 0 |
| 90 | Quality of life goes beyond the medical priorities in multiple sclerosis: assessing the impact of social support network. <i>Arquivos De Neuro-Psiquiatria</i> , 2017, 75, 263-264. | 0.8 | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 91 | Isolated rhombencephalitis with good clinical recovery. Arquivos De Neuro-Psiquiatria, 2017, 75, 757-757. | 0.8 | 0 |